Olomorasib is an investigational, selective KRAS G12C inhibitor with central nervous system activity. The phase 3 SUNRAY-01 ...
Danny Rischin, MD, on C-POST trial findings on prognostic value of ctDNA and DFS with adjuvant cemiplimab in high-risk CSCC.
John Bridgewater, BA, MBBS, MRCP, PHD, discusses the potential impact of the phase 3 HARMONi-GI1 trial on treating advanced ...
Johanna S. Enke, MD, discusses safety findings from the Re-LuPSMA trial of lutetium Lu-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results